Skip to content

Study · Animal study (in vivo) · rat · 2013

5 results

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability.

Klicek R, Kolenc D, Suran J, Drmic D, Brcic L, Aralica G, Sever M, Holjevac J, Radic B, Turudic T, Kokot A, Patrlj L, Rucman R, Seiwerth S, Sikiric P

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society1 Oct 2013Cited by 52 (Europe PMC)

PMID24304574 (opens in a new tab)PepBankPUB-24304574
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with cysteamine colitis, BPC‑157 induced healing, whereas controls could not heal.

    In plain wordsIn rats with colitis, BPC‑157 led to healing, while untreated control rats did not heal.

    Peptide
    BPC-157
    Outcome
    IncreaseCysteamine colitis healing
    Study

    ratn: not reported in source

    Cysteamine colitis (400 mg/kg intrarectally)
    Comparator
    Saline or drinking water controls
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml drinking water · intraperitoneal or per-oral (drinking water) · Until sacrifice at day 3, 5, 7 or 14As given in this study (rat).

    Source sentences

    Summary
    In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time.
    2 context sentences
    Summary · context
    For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used.
    Summary · context
    BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with colon-colon anastomosis, BPC‑157 induced healing, whereas controls could not heal.

    In plain wordsIn rats with a joined colon, BPC‑157 led to healing, while untreated control rats did not heal.

    Peptide
    BPC-157
    Outcome
    IncreaseColon-colon anastomosis healing
    Study

    ratn: not reported in source

    Colon-colon anastomosis
    Comparator
    Saline or drinking water controls
    Outcome group
    Wound healing · Gastrointestinal
    Studied dose
    10 µg/kg, 10 ng/kg (intraperitoneal); 0.16 µg/ml drinking water · intraperitoneal or per-oral (drinking water) · Until sacrifice at day 3, 5, 7 or 14As given in this study (rat).

    Source sentences

    Summary
    In general, the controls could not heal cysteamine colitis and colon-colon anastomosis. BPC 157 induced an efficient healing of both at the same time.
    2 context sentences
    Summary · context
    For colitis, cysteamine (400 mg/kg intrarectally (1 ml/rat)) and colon-colon anastomosis (sacrifice at day 3, 5, 7, and 14) were used.
    Summary · context
    BPC 157 (10 μg/kg, 10 ng/kg) was applied either intraperitoneally once time daily (first application immediately after surgery, last at 24 hours before sacrifice) or per-orally in drinking water (0.16 μg/ml/12 ml/day till the sacrifice) while controls simultaneously received an equivolume of saline…
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In cuprizone-treated rats, BPC‑157 gave less nerve damage in all damaged brain areas, especially in the most affected areas.

    In plain wordsIn rats given cuprizone, BPC‑157 reduced nerve damage in the brain compared with rats given cuprizone alone.

    Peptide
    BPC-157
    Outcome
    DecreaseNerve damage in brain areas (cuprizone model)
    Study

    ratn: not reported in source

    Cuprizone toxic model of multiple sclerosis
    Comparator
    Cuprizone controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg or 10 ng/kg intragastrically/day plus 0.16 µg or 0.16 ng/ml in drinking water · intragastric and drinking water · Until sacrifice at day 4As given in this study (rat).

    Source sentences

    Summary
    BPC 157-cuprizone rats had consistently less nerve damage in all damaged areas, especially in those areas that otherwise were most affected.
    1 context sentence
    Summary · context
    A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In cuprizone-treated rats, BPC‑157 counteracted cerebellar ataxia.

    In plain wordsIn rats given cuprizone, BPC‑157 reduced loss of balance and movement control from cerebellar damage.

    Peptide
    BPC-157
    Outcome
    DecreaseCerebellar ataxia (cuprizone model)
    Study

    ratn: not reported in source

    Cuprizone toxic model of multiple sclerosis
    Comparator
    Cuprizone controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg or 10 ng/kg intragastrically/day plus 0.16 µg or 0.16 ng/ml in drinking water · intragastric and drinking water · Until sacrifice at day 4As given in this study (rat).

    Source sentences

    Summary
    BPC 157 counteracted cerebellar ataxia and impaired forelimb function.
    1 context sentence
    Summary · context
    A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In cuprizone-treated rats, BPC‑157 counteracted impaired forelimb function.

    In plain wordsIn rats given cuprizone, BPC‑157 countered the loss of front limb function.

    Peptide
    BPC-157
    Outcome
    IncreaseForelimb function (cuprizone model)
    Study

    ratn: not reported in source

    Cuprizone toxic model of multiple sclerosis
    Comparator
    Cuprizone controls
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 µg or 10 ng/kg intragastrically/day plus 0.16 µg or 0.16 ng/ml in drinking water · intragastric and drinking water · Until sacrifice at day 4As given in this study (rat).

    Source sentences

    Summary
    impaired forelimb function.
    1 context sentence
    Summary · context
    A multiple sclerosis suited toxic rat model, cuprizone (compared with standard, a several times higher regimen, 2.5% of diet regimen + 1 g/kg intragastrically/day) was combined with BPC 157 (in drinking water 0.16 μg or 0.16 ng/ml/12 ml/day/rat + 10 μg or 10 ng/kg intragastrically/day) till the sacrifice at day 4.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.